- Home
- LXEO vs MNPR Comparison
LXEO vs MNPR Comparison
Compare LXEO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- MNPR
- Stock Information
- Founded
- LXEO 2017
- MNPR 2014
- Country
- LXEO United States
- MNPR United States
- Employees
- LXEO N/A
- MNPR N/A
- Industry
- LXEO
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- MNPR Health Care
- Exchange
- LXEO Nasdaq
- MNPR Nasdaq
- Market Cap
- LXEO 257.0M
- MNPR 248.8M
- IPO Year
- LXEO 2023
- MNPR 2019
- Fundamental
- Price
- LXEO $4.79
- MNPR $35.86
- Analyst Decision
- LXEO Strong Buy
- MNPR Strong Buy
- Analyst Count
- LXEO 6
- MNPR 7
- Target Price
- LXEO $17.17
- MNPR $62.00
- AVG Volume (30 Days)
- LXEO 398.4K
- MNPR 20.0K
- Earning Date
- LXEO 08-14-2025
- MNPR 08-12-2025
- Dividend Yield
- LXEO N/A
- MNPR N/A
- EPS Growth
- LXEO N/A
- MNPR N/A
- EPS
- LXEO N/A
- MNPR N/A
- Revenue
- LXEO N/A
- MNPR N/A
- Revenue This Year
- LXEO N/A
- MNPR N/A
- Revenue Next Year
- LXEO N/A
- MNPR N/A
- P/E Ratio
- LXEO N/A
- MNPR N/A
- Revenue Growth
- LXEO N/A
- MNPR N/A
- 52 Week Low
- LXEO $1.45
- MNPR $2.15
- 52 Week High
- LXEO $12.76
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- LXEO 59.85
- MNPR 44.06
- Support Level
- LXEO $4.34
- MNPR $30.51
- Resistance Level
- LXEO $4.96
- MNPR $42.50
- Average True Range (ATR)
- LXEO 0.36
- MNPR 3.29
- MACD
- LXEO 0.01
- MNPR -1.14
- Stochastic Oscillator
- LXEO 76.59
- MNPR 38.02
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.